The economic value of reducing medication dosing frequency with drug delivery technologies: An evidence assessment

Journal of Medical Economics

Volumn 13, Issue 2, 2010, Pages 193-202

  Cheng, Mindy M ^a   Alfonso, Rafael ^a   Best, Jennie H ^b   Garrison, Louis P ^a   Bruhn, David ^c   Veenstra, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Cost effectiveness; Dosing frequency; Drug delivery; Formulation change

Indexed keywords

ALPHA2B INTERFERON; METHYLPHENIDATE; OXYBUTYNIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; RISPERIDONE;

ATTENTION DEFICIT DISORDER; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; EVIDENCE BASED MEDICINE; HEALTH ECONOMICS; HEPATITIS C; HUMAN; LIFESPAN; MEDICAL LITERATURE; OVERACTIVE BLADDER; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; REVIEW; SCHIZOPHRENIA; URGE INCONTINENCE;

COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 77953340359     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696991003757500     Document Type: Review

References (40)

1. Rathbone MJ, Hadgraft J, Roberts MS, et al. Modified-Release Drug Delivery Technology. 2nd ed., Vol.2, New York: Informa Healthcare USA, 2008.
2. Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009;6:1-16.
3. Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009;15:e22-33.
4. "Fact Sheet Medisorb-Microspheres Technology" Accessed June 30, 2009: http://www.alkermes.com/media/42408/general%20medisorb% 20techonology%20fact%20sheet%20jan%202009%20-%20011409% 20.pdf
5. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed.. New York: Oxford University Press, 2005.
6. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in Health and Medicine.. New York: Oxford University Press, 1996.
7. Chiou CF, Hay JW, Wallace JF, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care 2003;41:32-44.
8. Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-näve chronic hepatitis C. Pharmacoeconomics 2004;22:257-265. (Pubitemid 38393394)
9. Sullivan SD, Jensen DM, Bernstein DE, et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 2004;99:1490-1496.
10. Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha-2a and 2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004;8:1-125iii-iv.
11. Shepherd J, Brodin HF, Cave CB, et al. Clinical and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care 2005;21:47-54.
12. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-593.
13. Pedder SCJ. Pegylation of interferon alfa: structural and pharmacokinetic properties. Semin Liver Dis 2003;23 (Suppl 1):19-22.
14. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 2009;180:400-407.
15. Olivares JM, Rodriguez-Martinez A, Burón JA, et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12 and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008;6:41-53.
16. Hughes DA, Dubois D. Cost-effectiveness analysis of extendedrelease formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics 2004;22:1047-1059.
17. Grishchenko M, Grieve RD, Sweeting MJ, et al. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care 2009;25:171-180.
18. Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-205iii.
19. Eldar-Lissai A, Cosler LE, Culakova E, et al. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008;11:172-179.
20. Annemans L, Warie H, Nechelput M, et al. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients. Acta Gastroenterol Belg 2004;67:1-8.
21. Guest JF, Abegunde D, Ruiz FJ. Cost effectiveness of controlledrelease oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria. Clin Drug Invest 2004;24:305-321.
22. Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon-2b plus ribavirin versus interferon-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52: 425-432.
23. Buti M, Medina M, Casado MA, et al. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of näve patients with chronic hepatitis C. Aliment Pharmacol Ther 2003;17:687-694. (Pubitemid 36418893)
24. Simon K, Gladysz A, Rotter K, et al. Cost effectiveness of replacing recombinated interferon-2b with its pegylated form in combination with ribavirin for the therapy of chronic HCV infection in Poland. Adv Clin Exp Med 2006;15:453-462.
25. Faber A, van Agthoven M, Kalverdijk LJ, et al. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. CNS Drugs 2008;22:157-170.
26. Edwards NC, Locklear JC, Rupnow MFT, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005;23 (Suppl 1):75-89.
27. Wertheimer AI, Santella TM, Finestone AJ, et al. Drug delivery systems improve pharmaceutical profile and facilitate medication adherence. Adv Ther 2005;22:559-577.
28. Shi L, Hodges M, Yurgin N, et al. Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006). Expert Rev Pharmacoecon Outcomes Res 2007;7:1-16.
29. Richter A, Anton SF, Koch P, et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-2335.
30. Haeusler JMC. Change in formulation and its potential clinical and pharmacoeconomic value: example of extended release venlafaxine. Curr Med Res Opin 2009;25:1089-1094.
31. Lemke TL, Williams DA, Roche VF, et al. Foye's Principles of Medicinal Chemistry. 6th ed.. Baltimore: Lippincott, Williams & Wilkins, 2007.
32. Hughes D. Less is more: medicines that require less frequent administration improve adherence, but are they better? Pharmacoeconomics 2006;24:211-213.
33. Möller HJ. Long-acting injectable risperidone for the treatment of schizophrenia. Drugs 2007;67:1541-1566.
34. Taylor M, Currie A, Lloyd K, et al. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmacol 2008;22:128-131.
35. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132.
36. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15:111-117.
37. Manns MP, McHutchison JG, Gordon SF, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-965.
38. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343: 1666-1672.
39. Lindsay KL, Trepo C, Heintges T, et al. A randomized, doubleblind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
40. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.